To evaluate the in-vivo role of PD-L1 expression on tumor cells, the CRISPR/Cas9 approach was applied for the genetic introduction of indel mutations into the PD-L1 encoding gene expressed on the surface of the A20 leukemia cell line to abolish protein expression (30, 31). Here, CD274 is linked to neoplasm.